Veracyte, Inc. (VCYT): Price and Financial Metrics


Veracyte, Inc. (VCYT): $27.25

0.08 (+0.29%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VCYT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

VCYT POWR Grades

  • VCYT scores best on the Growth dimension, with a Growth rank ahead of 71.99% of US stocks.
  • VCYT's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • VCYT's current lowest rank is in the Momentum metric (where it is better than 1.12% of US stocks).

VCYT Stock Summary

  • The price/operating cash flow metric for VERACYTE INC is higher than 98.46% of stocks in our set with a positive cash flow.
  • For VCYT, its debt to operating expenses ratio is greater than that reported by only 13.11% of US equities we're observing.
  • VCYT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 7.91% of US stocks.
  • If you're looking for stocks that are quantitatively similar to VERACYTE INC, a group of peers worth examining would be KTOS, KRMD, ATRC, HSKA, and VSAT.
  • VCYT's SEC filings can be seen here. And to visit VERACYTE INC's official web site, go to www.veracyte.com.

VCYT Valuation Summary

  • In comparison to the median Healthcare stock, VCYT's EV/EBIT ratio is 602.3% lower, now standing at -43.7.
  • Over the past 111 months, VCYT's price/sales ratio has gone down 16.2.

Below are key valuation metrics over time for VCYT.

Stock Date P/S P/B P/E EV/EBIT
VCYT 2022-12-02 7.4 2.0 -48.4 -43.7
VCYT 2022-12-01 7.3 2.0 -47.8 -43.2
VCYT 2022-11-30 7.0 1.9 -46.0 -41.4
VCYT 2022-11-29 6.4 1.7 -42.3 -37.8
VCYT 2022-11-28 6.4 1.7 -41.9 -37.4
VCYT 2022-11-25 6.6 1.8 -43.5 -39.0

VCYT Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -205.97%.
  • Its 4 year net cashflow from operations growth rate is now at 73.12%.
  • Its 2 year cash and equivalents growth rate is now at 6.91%.
VCYT's revenue has moved up $163,207,000 over the prior 33 months.

The table below shows VCYT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 283.575 6.237 -43.244
2022-06-30 268.353 -2.182 -48.65
2022-03-31 250.594 0.068 -48.156
2021-12-31 219.514 -31.621 -75.563
2021-09-30 186.714 -37.806 -73.079
2021-06-30 157.465 -34.661 -63.074

VCYT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VCYT has a Quality Grade of D, ranking ahead of 19.15% of graded US stocks.
  • VCYT's asset turnover comes in at 0.213 -- ranking 68th of 81 Healthcare stocks.
  • CHE, HCSG, and NTRA are the stocks whose asset turnover ratios are most correlated with VCYT.

The table below shows VCYT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.213 0.673 -1.427
2021-03-31 0.224 0.662 -1.543
2020-12-31 0.327 0.647 -0.827
2020-09-30 0.360 0.642 -0.795
2020-06-30 0.425 0.652 -0.693
2020-03-31 0.462 0.670 -0.490

VCYT Price Target

For more insight on analysts targets of VCYT, see our VCYT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $63.17 Average Broker Recommendation 1.5 (Moderate Buy)

VCYT Stock Price Chart Interactive Chart >

Price chart for VCYT

VCYT Price/Volume Stats

Current price $27.25 52-week high $45.58
Prev. close $27.17 52-week low $14.85
Day low $26.63 Volume 722,400
Day high $28.09 Avg. volume 954,930
50-day MA $21.62 Dividend yield N/A
200-day MA $22.23 Market Cap 1.96B

Veracyte, Inc. (VCYT) Company Bio


Veracyte Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company was founded in 2006 and is based in San Francisco, California.


VCYT Latest News Stream


Event/Time News Detail
Loading, please wait...

VCYT Latest Social Stream


Loading social stream, please wait...

View Full VCYT Social Stream

Latest VCYT News From Around the Web

Below are the latest news stories about VERACYTE INC that investors may wish to consider to help them evaluate VCYT as an investment opportunity.

Veracyte Third Quarter 2022 Earnings: Beats Expectations

Veracyte ( NASDAQ:VCYT ) Third Quarter 2022 Results Key Financial Results Revenue: US$75.6m (up 25% from 3Q 2021). Net...

Yahoo | November 9, 2022

Veracyte Q3 Earnings: Good Execution; Sustainable Rally

Veracyte Q3 earnings exceeded expectations. Read more to see my thoughts on VCYT''s latest numbers and why I''m bullish on the stock now.

Seeking Alpha | November 5, 2022

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Veracyte (VCYT) and Moderna (MRNA)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Veracyte (VCYT – Research Report) and Moderna (MRNA – Research Report). Insulet (PODD) In a report released today, Cecilia Furlong from Morgan Stanley maintained a Hold rating on Insulet, with a price target of $300.00. The company's shares closed last Friday at $300.05. According to TipRanks.

Catie Powers on TipRanks | November 4, 2022

Veracyte rises 10.6% after company raises full-year forecast

Veracyte (VCYT) is trading 10.6% higher premarket after the company raised its full-year 2022 forecast and posted 25% Y/Y rise in quarterly revenue, helped by strong performance…

Seeking Alpha | November 3, 2022

Veracyte Reports 32 Percent Q3 Revenue Growth, Raises Full-Year Guidance

The firm said that its Decipher and Afirma tests each benefitted from expanded coverage and largely drove growth this quarter.

GenomeWeb | November 2, 2022

Read More 'VCYT' Stories Here

VCYT Price Returns

1-mo 10.19%
3-mo 40.54%
6-mo 66.87%
1-year -33.86%
3-year -6.61%
5-year 321.83%
YTD -33.86%
2021 -15.82%
2020 75.29%
2019 121.94%
2018 92.65%
2017 -15.63%

Continue Researching VCYT

Want to see what other sources are saying about Veracyte Inc's financials and stock price? Try the links below:

Veracyte Inc (VCYT) Stock Price | Nasdaq
Veracyte Inc (VCYT) Stock Quote, History and News - Yahoo Finance
Veracyte Inc (VCYT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6138 seconds.